Atıf İçin Kopyala
Powles T., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y., ...Daha Fazla
LANCET ONCOLOGY, cilt.22, sa.7, ss.931-945, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
22
Sayı:
7
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1016/s1470-2045(21)00152-2
-
Dergi Adı:
LANCET ONCOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.931-945
-
İstanbul Üniversitesi Adresli:
Hayır
Özet
Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.